Database release
Added entries:
- (FDA) BRCA1 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
- (FDA) BRCA2 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
- (FDA) MSI-H and sensitivity to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, in endometrial cancer.
Revised entries:
- (FDA) EGFR p.T790M and sensitivity to osimertinib, resolved typo in description.
- (FDA) RET fusions and sensitivity to pralsetinib, received regular approval from FDA after being previously granted accelerated approval.
- All prior entries have been revised to have
last_updateddate be in ISO 8601 date standard ofYYYY-MM-DD
Removed entries:
- (FDA) RET somatic variants and sensitivity to pralsetinib in medullary thyroid cancer was withdrawn voluntarily by Genentech.
The field publication_date has been added to entries added or modified in this release. Our team will populate this field for prior records over future releases.